AbbVie Inc. Quarterly Interest Expense in USD from Q3 2012 to Q2 2024

Taxonomy & unit: us-gaap: USD
Description: Amount of the cost of borrowed funds accounted for as interest expense.
Summary: AbbVie Inc. quarterly/annual Interest Expense history and growth rate from Q3 2012 to Q2 2024.
AbbVie Inc. Interest Expense for the quarter ending June 30, 2024 was $726M, a 31.5% increase year-over-year.
AbbVie Inc. Interest Expense for the twelve months ending June 30, 2024 was $2.51B, a 12.3% increase year-over-year.
AbbVie Inc. annual Interest Expense for 2023 was $2.22B, a 0.27% decline from 2022.
AbbVie Inc. annual Interest Expense for 2022 was $2.23B, a 7.97% decline from 2021.
AbbVie Inc. annual Interest Expense for 2021 was $2.42B, a 1.26% decline from 2020.

Interest Expense, Trailing 12 Months (USD)

Interest Expense, Quarterly (USD)

Interest Expense, YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q2 2024	$2.51B	$726M	+$174M	+31.5%	Apr 1, 2024	Jun 30, 2024	10-Q	2024-08-07
Q1 2024	$2.33B	$660M	+$107M	+19.3%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-05-03
Q4 2023	$2.22B	$564M	-$2M	-0.35%	Oct 1, 2023	Dec 31, 2023	10-K	2024-02-20
Q3 2023	$2.23B	$555M	-$5M	-0.89%	Jul 1, 2023	Sep 30, 2023	10-Q	2023-11-06
Q2 2023	$2.23B	$552M	-$4M	-0.72%	Apr 1, 2023	Jun 30, 2023	10-Q	2024-08-07
Q1 2023	$2.24B	$553M	+$5M	+0.91%	Jan 1, 2023	Mar 31, 2023	10-Q	2024-05-03
Q4 2022	$2.23B	$566M	-$14M	-2.41%	Oct 1, 2022	Dec 31, 2022	10-K	2024-02-20
Q3 2022	$2.24B	$560M	-$36M	-6.04%	Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-06
Q2 2022	$2.28B	$556M	-$59M	-9.59%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-07
Q1 2022	$2.34B	$548M	-$84M	-13.3%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-05
Q4 2021	$2.42B	$580M	-$49M	-7.79%	Oct 1, 2021	Dec 31, 2021	10-K	2024-02-20
Q3 2021	$2.47B	$596M	-$34M	-5.4%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-04
Q2 2021	$2.51B	$615M	-$17M	-2.69%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-04
Q1 2021	$2.52B	$632M	+$69M	+12.3%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-06
Q4 2020	$2.45B	$629M	+$70M	+12.5%	Oct 1, 2020	Dec 31, 2020	10-K	2023-02-17
Q3 2020	$2.38B	$630M	+$150M	+31.3%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-02
Q2 2020	$2.23B	$632M	+$274M	+76.5%	Apr 1, 2020	Jun 30, 2020	10-Q	2021-08-02
Q1 2020	$1.96B	$563M	+$176M	+45.5%	Jan 1, 2020	Mar 31, 2020	10-Q	2021-05-07
Q4 2019	$1.78B	$559M	+$179M	+47.1%	Oct 1, 2019	Dec 31, 2019	10-K	2022-02-18
Q3 2019	$1.61B	$480M	+$141M	+41.6%	Jul 1, 2019	Sep 30, 2019	10-Q	2020-11-04
Q2 2019	$1.46B	$358M	+$38M	+11.9%	Apr 1, 2019	Jun 30, 2019	10-Q	2020-08-04
Q1 2019	$1.43B	$387M	+$78M	+25.2%	Jan 1, 2019	Mar 31, 2019	10-Q	2020-05-08
Q4 2018	$1.35B	$380M	+$80M	+26.7%	Oct 1, 2018	Dec 31, 2018	10-K	2021-02-19
Q3 2018	$1.27B	$339M	+$46M	+15.7%	Jul 1, 2018	Sep 30, 2018	10-Q	2019-11-06
Q2 2018	$1.22B	$320M	+$36M	+12.7%	Apr 1, 2018	Jun 30, 2018	10-Q	2019-08-05
Q1 2018	$1.19B	$309M	+$36M	+13.2%	Jan 1, 2018	Mar 31, 2018	10-Q	2019-05-03
Q4 2017	$1.15B	$300M	-$16M	-5.06%	Oct 1, 2017	Dec 31, 2017	10-K	2020-02-21
Q3 2017	$1.17B	$293M	+$22M	+8.12%	Jul 1, 2017	Sep 30, 2017	10-Q	2018-11-07
Q2 2017	$1.14B	$284M	+$39M	+15.9%	Apr 1, 2017	Jun 30, 2017	10-Q	2018-08-07
Q1 2017	$1.11B	$273M	+$58M	+27%	Jan 1, 2017	Mar 31, 2017	10-Q	2018-05-04
Q4 2016	$1.05B	$316M	+$108M	+51.9%	Oct 1, 2016	Dec 31, 2016	10-K	2019-02-27
Q3 2016	$939M	$271M	+$64M	+30.9%	Jul 1, 2016	Sep 30, 2016	10-Q	2017-11-07
Q2 2016	$875M	$245M	+$73M	+42.4%	Apr 1, 2016	Jun 30, 2016	10-Q	2017-08-07
Q1 2016	$802M	$215M	+$83M	+62.9%	Jan 1, 2016	Mar 31, 2016	10-Q	2017-05-05
Q4 2015	$719M	$208M	+$70M	+50.7%	Oct 1, 2015	Dec 31, 2015	10-K	2018-02-16
Q3 2015	$649M	$207M	+$59M	+39.9%	Jul 1, 2015	Sep 30, 2015	10-Q	2016-11-07
Q2 2015	$590M	$172M	+$99M	+136%	Apr 1, 2015	Jun 30, 2015	10-Q	2016-08-05
Q1 2015	$491M	$132M	+$62M	+88.6%	Jan 1, 2015	Mar 31, 2015	10-Q	2016-05-06
Q4 2014	$429M	$138M	+$65M	+89%	Oct 1, 2014	Dec 31, 2014	10-K	2017-02-17
Q3 2014	$364M	$148M	+$73M	+97.3%	Jul 1, 2014	Sep 30, 2014	10-Q	2015-11-06
Q2 2014	$291M	$73M	-$6M	-7.6%	Apr 1, 2014	Jun 30, 2014	10-Q	2015-08-07
Q1 2014	$297M	$70M	-$2M	-2.78%	Jan 1, 2014	Mar 31, 2014	10-Q	2015-05-08
Q4 2013	$299M	$73M			Oct 1, 2013	Dec 31, 2013	10-K	2016-02-19
Q3 2013		$75M	+$65M	+650%	Jul 1, 2013	Sep 30, 2013	10-Q	2014-11-07
Q2 2013		$79M			Apr 1, 2013	Jun 30, 2013	10-Q	2014-08-07
Q1 2013		$72M			Jan 1, 2013	Mar 31, 2013	10-Q	2014-05-09
Q3 2012		$10M			Jul 1, 2012	Sep 30, 2012	10-Q	2013-11-12

* An asterisk sign (*) next to the value indicates that the value is likely invalid.